TIRZEPATIDE 120mg

Tirzepatide is a 39–amino acid dual incretin receptor agonist that activates both GLP‑1 and GIP receptors, enhancing glucose‑dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite^[1][2]. Its ~5‑day half‑life allows convenient once‑weekly subcutaneous dosing^[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLP‑1 agonists^[3][4].

• Reconstitute: Add 5.0 mL bacteriostatic water → 120.0 mg/mL concentration.
• Typical weekly range: 2.5–15 mg once weekly (gradual 4‑week titration steps).
• • Easy measuring: At 24 mg/mL, 1 unit = 0.01 mL = 0.24 mg = 240 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days.

  Standard / Gradual Approach (5 mL = 24 mg/mL)

  Phase	Weekly Dose	Units per Injection
  Weeks 1–4	2.5 mg	10.4 units (0.104 mL) × 1 injection
  Weeks 5–8	5 mg	20.8 units (0.208 mL) × 1 injection
  Weeks 9–12	7.5 mg	31.25 units (0.313 mL) × 1 injection
  Weeks 13–16	10 mg	41.7 units (0.417 mL) × 1 injection

  Frequency: Inject once weekly subcutaneously on the same day each week. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

1. Draw 5.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
5. Use within 28 days of reconstitution^[6].